On the hydrolytic stability of unsymmetric platinum(iv) anticancer prodrugs containing axial halogens
- 6 May 2021
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in Inorganic Chemistry Frontiers
- Vol. 8 (16), 3794-3802
- https://doi.org/10.1039/d1qi00208b
Abstract
The longstanding notion that Pt(IV) complexes are inert under physiological conditions where there are limited reducing agents is facing a great challenge. Herein, we systematically investigated the hydrolytic stability of a wide range of unsymmetric Pt(IV) anticancer prodrugs built upon clinical Pt(II) drugs. The detailed structure–stability relationship shows that the hydrolytic stability of one certain axial ligand in Pt(IV) complexes can be dramatically affected by the other five ligands; both the coordination environment of equatorial ligands and the “trans influence” from one axial ligand affect the hydrolytic stability of the counter axial ligand, and the more electronegative axial ligand faces the higher possibility to detach. Inspiringly, this newly discovered structure–stability relationship has been successfully applied to improve the hydrolytic stability of Pt(IV) complexes that contain axial dichloroacetato ligands. Our discovery represents a significant advancement in the theory of the chemical inertness of Pt(IV) complexes toward ligand exchange reactions and provides a practical guide for the future design of Pt(IV) anticancer prodrugs.Keywords
Funding Information
- National Natural Science Foundation of China (21877092, 22077108)
- Research Grants Council, University Grants Committee (CityU 11307419, CityU 11304318, CityU 11303320)
This publication has 51 references indexed in Scilit:
- A Photocaged, Water-Oxidizing, and Nucleolus-Targeted Pt(IV) Complex with a Distinct Anticancer MechanismJournal of the American Chemical Society, 2020
- Phorbiplatin, a Highly Potent Pt(IV) Antitumor Prodrug That Can Be Controllably Activated by Red LightChem, 2019
- Multi-action Pt(IV) anticancer agents; do we understand how they work?Journal of Inorganic Biochemistry, 2018
- Monochalcoplatin: An Actively Transported, Quickly Reducible, and Highly Potent PtIV Anticancer ProdrugAngewandte Chemie, 2018
- A Quadruple‐Action Platinum(IV) Prodrug with Anticancer Activity Against KRAS Mutated Cancer Cell LinesAngewandte Chemie, 2017
- A Platinum(IV) Anticancer Prodrug Targeting Nucleotide Excision Repair To Overcome Cisplatin ResistanceAngewandte Chemie, 2016
- The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) ProdrugsChemical Reviews, 2016
- Metal-based anticancer chemotherapeutic agentsCurrent Opinion in Chemical Biology, 2014
- Synthetic Methods for the Preparation of Platinum Anticancer ComplexesChemical Reviews, 2013
- The status of platinum anticancer drugs in the clinic and in clinical trialsDalton Transactions, 2010